 All adverse events will be collected during the period of Visit 1 Day 0 to Visit 2 between Day 21 and Day 28; Serum samples for immunogenicity assays will be collected immediately before immunization on Visit 1 Day 0 and on Visit 2 between Day 21 and Day 28 in all subjects. Immunogenicity will be evaluated by HI test. 